uniQure (NASDAQ:QURE) Issues Quarterly Earnings Results, Beats Estimates By $0.21 EPS

uniQure (NASDAQ:QURE) issued its quarterly earnings data on Tuesday. The biotechnology company reported ($0.91) EPS for the quarter, beating the consensus estimate of ($1.12) by $0.21, Zacks reports. The business had revenue of $2.29 million during the quarter, compared to the consensus estimate of $2.73 million. uniQure had a negative net margin of 1,027.52% and a negative return on equity of 158.09%.

uniQure Stock Performance

QURE traded up $0.38 during midday trading on Thursday, reaching $7.54. The company had a trading volume of 761,926 shares, compared to its average volume of 1,411,609. The company has a debt-to-equity ratio of 1.06, a quick ratio of 7.36 and a current ratio of 7.36. The stock has a market cap of $367.20 million, a PE ratio of -1.27 and a beta of 0.90. uniQure has a 12-month low of $3.73 and a 12-month high of $11.35. The business has a 50-day moving average price of $5.70 and a two-hundred day moving average price of $5.79.

Analyst Ratings Changes

Several equities analysts recently commented on QURE shares. HC Wainwright reissued a “buy” rating and issued a $25.00 price objective on shares of uniQure in a research note on Wednesday. Cantor Fitzgerald reissued an “overweight” rating and issued a $28.00 price objective on shares of uniQure in a research note on Wednesday. The Goldman Sachs Group dropped their price target on shares of uniQure from $10.00 to $9.00 and set a “neutral” rating for the company in a research note on Wednesday. Royal Bank of Canada dropped their price target on shares of uniQure from $16.00 to $14.00 and set an “outperform” rating for the company in a research note on Wednesday. Finally, Raymond James reaffirmed an “outperform” rating and set a $20.00 price target on shares of uniQure in a research note on Thursday, October 10th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. According to MarketBeat, uniQure currently has an average rating of “Hold” and a consensus price target of $17.00.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.